Our vision for bioelectronic medicines is one of miniature, implantable devices that can be attached to individual peripheral nerves anywhere in the viscera.

Such devices would be able to decipher and modulate neural signalling patterns, bringing about therapeutic effects targeted at single functions of specific organs. GSK operates an exploratory research funding program; we have established a $50 million venture arm dedicated to technology and early bioelectronic treatment manifestations and an innovation challenge focussed on rapidly bringing visceral nerve research platforms to the community.